share_log

Needham Reiterates Buy on Sarepta Therapeutics, Maintains $235 Price Target

Needham Reiterates Buy on Sarepta Therapeutics, Maintains $235 Price Target

Needham再次买入Sarepta Therapeutics,并维持235美元的目标价
Benzinga ·  06/27 06:06

Needham analyst Gil Blum reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and maintains $235 price target.

Needham分析师吉尔·布卢姆重申买入Sarepta Therapeutics (纳斯达克: SRPT),并维持235美元的目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发